stoxline Quote Chart Rank Option Currency Glossary
  
Puma Biotechnology, Inc. (PBYI)
3.04  0.18 (6.29%)    04-22 15:56
Open: 2.86
High: 3.04
Volume: 163,708
  
Pre. Close: 2.86
Low: 2.86
Market Cap: 151(M)
Technical analysis
2025-04-22 3:19:32 PM
Short term     
Mid term     
Targets 6-month :  3.75 1-year :  4.21
Resists First :  3.21 Second :  3.6
Pivot price 2.89
Supports First :  2.57 Second :  2.14
MAs MA(5) :  2.91 MA(20) :  2.95
MA(100) :  3.06 MA(250) :  3.19
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  64 D(3) :  54.2
RSI RSI(14): 50.4
52-week High :  5.26 Low :  2.23
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PBYI ] has closed below upper band by 7.3%. Bollinger Bands are 59.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.87 - 2.89 2.89 - 2.9
Low: 2.72 - 2.73 2.73 - 2.75
Close: 2.84 - 2.86 2.86 - 2.88
Company Description

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Headline News

Mon, 21 Apr 2025
Is the Options Market Predicting a Spike in Puma Biotechnology Stock? - Yahoo Finance

Fri, 11 Apr 2025
Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential - Seeking Alpha

Wed, 02 Apr 2025
Puma Biotech Expands Team: New Hires Receive Strategic Stock Compensation Package - Stock Titan

Sat, 29 Mar 2025
Further weakness as Puma Biotechnology (NASDAQ:PBYI) drops 11% this week, taking five-year losses to 55% - simplywall.st

Wed, 26 Mar 2025
Groundbreaking Clinical Trial: Neratinib's Novel Combination Approach Targets HER2 Tumors - Stock Titan

Wed, 26 Mar 2025
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025 - BioSpace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 50 (M)
Shares Float 42 (M)
Held by Insiders 15.3 (%)
Held by Institutions 59.2 (%)
Shares Short 2,790 (K)
Shares Short P.Month 3,070 (K)
Stock Financials
EPS 0.62
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.87
Profit Margin 13.1 %
Operating Margin 22.6 %
Return on Assets (ttm) 8.7 %
Return on Equity (ttm) 41.5 %
Qtrly Rev. Growth -18.3 %
Gross Profit (p.s.) 3.34
Sales Per Share 4.64
EBITDA (p.s.) 0.85
Qtrly Earnings Growth 58.5 %
Operating Cash Flow 39 (M)
Levered Free Cash Flow 29 (M)
Stock Valuations
PE Ratio 4.86
PEG Ratio 0
Price to Book value 1.6
Price to Sales 0.64
Price to Cash Flow 3.84
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android